Recovering scientist turned early stage VC A biotech optimist fighting gravity

Beyond the CEO: Building An Effective Leadership Team  
March 15, 2018

This blog was written by Ankit Mahadevia, CEO of Spero Therapeutics and Atlas Advisor, as part of the From The Trenches feature of LifeSciVC.   The biotech twittersphere recently engaged in very thoughtful debate (resulting in a great piece by

Leave a comment

Allostery: Realizing The Promise
March 5, 2018

This blog was written by Jonathan Montagu, CEO of Hotspot Therapeutics and Atlas EIR, as part of the From The Trenches feature of LifeSciVC. It starts off with flu-like symptoms and progresses to a perpetual low-grade fever, excessive sweating and

Leave a comment

Celebrating Rare Disease Day
February 28, 2018

Today we recognize and celebrate #RareDiseaseDay to raise awareness of rare diseases and their impact on patients’ lives. Nearly 1 out of 10 Americans lives with a rare disease – more than 30M people in the United States.  NORD has documented over

Leave a comment

Grey Hair In the C-Suite: Experience, Age, And IPOs In Biotech
February 26, 2018

Biotech venture investors often prefer to back executives and entrepreneurs with a bit of grey hair. Seasoned industry veterans that possess leadership charisma along with years of experience, and the oft-accompanying learned judgement, are highly sought-after in biopharma’s seemingly endless

Leave a comment

Two’s Company, Three’s Diversity
February 12, 2018

This blog was written by Ros Deegan, CBO of Bicycle Therapeutics, as part of the From The Trenches feature of LifeSciVC. Two years ago, Bloomberg Business published a feature entitled At Biotech Party, Gender Diversity Means Cocktail Waitresses. Within three

3 Comments

Bringing The Human Element Full Circle Thru Adaptive Ski Coaching
February 8, 2018

My experience as an adaptive ski coach has been nothing short of life-changing. I don’t say that with hyperbole. By bringing together my passion for the mountains with my profession as an investor in biomedical therapies, adaptive coaching completes the

Leave a comment

When Does Digital Health Become Just Healthcare?
February 7, 2018

This blog was written by Adam Rosenberg, CEO of Rodin Therapeutics, as part of the From The Trenches feature of LifeSciVC.   In 2015 I went to both the JPMorgan and CES conferences, back to back, and attended numerous can’t-miss dinners,

1 Comment

We Saw It Coming In Pharma: Now Gene Therapy Is Biotech 2.0 For Rare Diseases
February 1, 2018

This blog was written by Deanna Petersen, Chief Business Officer of AvroBio, as part of the From The Trenches feature of LifeSciVC.   It seems so clear now: gene therapy is on a roll.  As 2017 came to a close, the

1 Comment

So, Your Board Asked For A Deal This Year?
January 30, 2018

This blog was written by Jeb Keiper, CFO & CBO of Nimbus Therapeutics LLC, as part of the From The Trenches feature of LifeSciVC. A fresh Q1 is underway, your meetings at JPMorgan were top notch, and you have a

1 Comment

Two CARTs, Two Charts: Dissecting Returns From T-Cell Therapy M&A
January 23, 2018

Yesterday Celgene finalized its acquisition of Juno Therapeutics for $9B, only a few short months after Gilead bought Kite Pharma for $11.9B. With only a few hundred patients ever treated with their therapies, $20B represents a lot of promise in

Leave a comment

Reaping What We Sow: Seeds Planted Long Ago Prepare to Bear Fruit In 2018
January 17, 2018

This blog was written by Michael Gladstone, Principal at Atlas Venture, as part of the From The Trenches feature of LifeSciVC. Biotech newsflow came out the gate a little slow in 2018 (though it appears it may be speeding up

Leave a comment

Snow, Skiing, And My 2018 Outlook For Biotech
January 4, 2018

As 2018 begins, and we prepare for the biopharma sector’s annual kickoff in San Francisco next week, my thoughts are focused on the snow. I’m literally watching bombogenesis unleash a blizzard white-out in Boston right now. As a winter sports

1 Comment